Cash burn measures how quickly a business consumes cash. Cash runway estimates how long its available funding can support a stated spending plan. For a biotech company without dependable product revenue, these measures help answer a practical investment question: can the company reach its next meaningful development milestone before it needs more money?
The answer requires more than dividing a reported cash balance by last quarter’s spending. Trial costs change, manufacturing payments arrive unevenly, and a financing announcement does not always mean the proceeds have reached the bank. A useful runway assessment connects available liquidity with future payments, development timelines and a reasonable operating reserve. Within biotech financial analysis and valuation, that assessment helps distinguish a funded development plan from one that depends on another successful capital raise. It does not establish whether the science will work or whether the shares offer good value.
What cash burn and cash runway measure
Cash burn is an analytical measure, so define it before comparing companies. Operating cash burn usually refers to net cash used in operating activities. A broader measure adds capital expenditure, such as spending on laboratory equipment or a manufacturing facility. Gross burn describes cash spending before operating receipts; net burn deducts those receipts. A business receiving collaboration payments can therefore report much lower net burn than its underlying spending would suggest. For runway analysis, use a clearly stated measure that captures the cash demands of the operating plan, then model financing separately.
Simple cash runway in months = available cash ÷ expected monthly net cash burn.
This formula assumes spending remains steady and that all cash in the numerator is available for use. Neither assumption should pass without inspection. A company preparing to start a large trial needs a different forecast from one closing study sites after its final patient visit. The distinction between early, clinical and commercial development stages matters because each stage carries a different spending schedule. Treat the simple calculation as a screening tool. The investment question concerns the cash remaining at a milestone, and the obligations that follow it.
Start with cash the company can actually use
Build the starting balance from cash, cash equivalents and investments that can reasonably fund the plan. Check the investment notes for liquidity, maturity and restrictions rather than assuming every financial asset is equivalent to a bank balance. Exclude restricted amounts that cannot pay ordinary development costs. If restricted cash already appears separately from the headline cash and investments figure, do not subtract it again. Accounts receivable, prepaid research expenses and laboratory equipment should not enter the numerator simply because they appear among the company’s assets. Their accounting value does not make them immediately spendable.
Use the balance sheet date, not the publication date, as the starting point. Cash reported at September 30 has already funded several weeks of operations when results arrive in November. Bridge that interval using estimated spending and any disclosed transactions completed after the reporting period. Keep confirmed proceeds separate from proposed transactions. The relevant documents include the financial statements, liquidity discussion and subsequent events notes; a disciplined process for researching biotech financial filings helps prevent an old balance from masquerading as current funding.
Debt requires a payment schedule rather than a blanket deduction. Principal due during the forecast period belongs in the cash bridge. Debt maturing several years later still matters, but subtracting it immediately can obscure how long current operations are funded. Conversely, ignoring an approaching repayment overstates runway. This differs from the net debt adjustments used in enterprise value calculations. Also distinguish a contractual cash requirement from an analyst’s operating reserve. Both may reduce usable headroom, but they represent different constraints and should remain visible.
Measure burn from the cash flow statement
Start with the cash flow statement rather than net loss. Accounting losses and cash consumption differ because expenses can include noncash charges, while payment timing changes operating assets and liabilities. Equipment purchases also consume cash outside operating activities. The separation between operating, investing and financing cash flows is set out in the SEC’s guide to financial statements. For a development company, a useful starting measure combines operating cash used with capital expenditure. Do not treat every investing outflow as development spending: buying marketable securities can simply move funds between cash and investments.
Match the reporting period to the calculation. If a filing presents cumulative cash flows, derive the latest quarter by subtracting the previous cumulative period. Suppose nine month operating cash use is $150 million and the six month figure was $85 million. The latest quarter consumed $65 million, not $50 million, the quarterly average across nine months. If capital expenditure was another $10 million in that latest quarter, broader burn was $75 million, or $25 million a month. The average and the latest quarter answer different questions. One smooths payment timing; the other may better capture an expanding development programme.
Separate repeatable spending from temporary cash movements
Keep reported burn intact, then build a separate forward estimate. A large collaboration receipt can reduce historical net burn without reducing future trial expenses. An exceptional legal payment can make one quarter look unusually expensive. The analysis should identify the transaction, show its treatment and explain why the next period will differ. Cash flow classification itself affects how investors interpret a business’s funding needs, a point addressed in the SEC statement on cash flow reporting quality. For runway modelling, distinguish a repeatable operating receipt from an exceptional payment without rewriting the reported accounts.
Payment timing deserves equal attention. A quarter with rising unpaid supplier bills may show restrained cash consumption even though the company has incurred substantial costs. A large advance payment can produce the reverse effect: cash leaves before the related expense appears. Review these movements before extrapolating. Do not automatically classify advance payments as waste, or delayed payments as savings. Stock based compensation also needs separate treatment. It is not a current cash payment, so it should not be added back into cash burn after the cash flow statement has already adjusted for it. Its ownership cost belongs elsewhere in the investment analysis.
A worked biotech cash runway example
Consider a fictional biotech company with a September 30, 2026 balance sheet and an expected clinical readout on June 30, 2027. Its available cash and liquid investments total $300 million after excluding restricted funds. The latest quarter’s operating cash use was $65 million, with another $10 million spent on equipment. Assume that $75 million quarterly pace continues. Management also expects a separate $15 million supplier payment that is not included in that recurring spending estimate. The analyst wants the company to retain a $30 million operating reserve. These assumptions are illustrative, not a recommended reserve level.
| Model input | Amount or timing | Treatment |
|---|---|---|
| Available cash and liquid investments | $300 million | Starting liquidity after restrictions |
| Latest quarterly operating cash use | $65 million | Recurring spending assumption |
| Quarterly capital expenditure | $10 million | Added to operating cash use |
| Expected monthly burn | $25 million | $75 million divided by three months |
| Separate supplier payment | $15 million | Additional cash outflow before the readout |
| Analyst’s operating reserve | $30 million | Cash retained rather than spent to zero |
| Time to expected readout | Nine months | Forecast funding period |
The simplest calculation gives 12 months of runway: $300 million divided by $25 million. That ignores both the supplier payment and the operating reserve. After allowing for them, spending capacity above the reserve is $255 million. At the assumed monthly burn, that represents 10.2 months. This adjusted figure describes time until the reserve is reached, assuming the supplier payment occurs before then. It is not the same as time until cash reaches zero, and it should not be labelled as though the two measures were interchangeable.
At the expected readout, nine months of recurring spending consumes $225 million. Deduct the $15 million supplier payment and the company has $60 million left. It can fund the readout under these assumptions. Its headroom above the reserve is only $30 million, however, equivalent to 1.2 months of further spending. A statement that the company is “funded through data” would therefore conceal an important distinction: it can reach the event, but has little room above the chosen reserve to operate afterward without financing or spending changes.
Match funding to a milestone that can change the investment case
Specify what the next milestone will establish. Starting a trial, completing recruitment and reporting interpretable efficacy data are different events. A company may be funded to open study sites yet still need capital before it can produce evidence that supports further development. Build the cash forecast around the event relevant to the investment thesis, rather than whichever date appears nearest on a presentation slide. The broader range of biotech trial, regulatory and partnership catalysts helps distinguish operational progress from events that may materially change a programme’s prospects.
A registry date also needs careful interpretation. The primary completion date concerns the final collection of primary outcome data; study completion includes final data collection for secondary outcomes and adverse events as well. These distinctions appear in the ClinicalTrials.gov study terms. Neither definition promises a public results announcement on that day. For the funding model, allow time for the work between collecting data and presenting an interpretable result. Then include an operating period after the announcement. Financing and partnership negotiations require time, even if the data support continued development.
Read management runway guidance as a spending plan
A historical example shows how runway guidance connects to development plans. On February 25, 2025, Beam Therapeutics reported $850.7 million in cash, cash equivalents and marketable securities at December 31, 2024. It expected those resources to fund anticipated operating expenses and capital expenditure into 2027, including funding directed at listed programme milestones. Those figures and assumptions appear in Beam’s fourth quarter and year end 2024 results. This is a dated example of guidance, not a statement of Beam’s current financial position. The wording links the estimate to an operating plan rather than a constant historical burn rate.
Read each part of comparable guidance carefully. “Into 2027” does not mean through December 31, 2027. Funding current plans does not establish that every possible trial expansion or launch expense is covered. Ask which programmes remain active, whether spending reductions have already occurred and whether anticipated receipts enter the forecast. A longer runway can reflect stronger funding, fewer development commitments or both. Compare successive statements on a consistent basis. If the company has stopped two programmes, its new runway cannot be interpreted as evidence that it can fund the old pipeline for longer.
Stress test delays and changes in spending
Return to the fictional company. If its readout moves three months later while monthly burn remains $25 million, recurring spending reaches $300 million over 12 months. The separate supplier payment creates a $15 million cash shortfall. To preserve the $30 million reserve, it would need $45 million of additional funding or equivalent spending reductions by that point. The scientific programme need not fail for the financing plan to fail. Timing alone can create the gap. Model the delay explicitly rather than adding an unexplained percentage contingency to the final runway figure.
Regulatory work can also extend the funding period. Additional studies and manufacturing deficiencies can delay approval, as detailed in the FDA’s explanation of drug review setbacks. Translate such a scenario into payments and time: what work continues, what new work begins, and when suppliers must be paid. A longer calendar period does not always mean proportionately higher spending, because some activities finish while others remain open. Use the type of regulatory setback to frame the scenario rather than assuming every delay has the same financial effect.
Test higher spending separately from later timing. In the example, a $30 million monthly burn rate would leave just $15 million at the original nine month readout after the supplier payment, below the chosen reserve. Successful development can create this pressure too. A larger study, additional patient cohorts or more production capacity may require spending before fresh capital arrives. Review manufacturing scale up and capacity commitments where they affect the forecast. A promising result can improve the development case while increasing the amount of cash needed to pursue it.
Financing pressure begins before cash runs out
A company does not need to approach zero cash before considering another raise. In the example, waiting until after the readout leaves little room above the reserve. Raising earlier could reduce that timing risk, though the terms determine the cost to existing shareholders. A shelf registration or an at the market offering arrangement should not be entered as cash received. Model proceeds when a transaction is completed, and use proceeds after transaction costs. The ownership consequences belong in a separate assessment of share dilution and equity financing risk. Raising money can protect the programme while reducing each existing share’s ownership percentage.
Debt needs a different cash bridge. Include interest, repayment dates and any conditions attached to additional borrowing. Do not assume the full advertised facility is available today if later advances depend on milestones or other requirements. A transaction can provide immediate funding while bringing forward another financing decision. The same principle applies to alternative structures: assess both the cash arriving now and the future payments or economic rights exchanged for it. A review of biotech debt and alternative financing helps keep those obligations separate from ordinary development burn.
Partnership receipts require another distinction. An upfront payment already received belongs in the cash balance. A future milestone should enter a scenario only when its contractual trigger, timing and collection assumptions are clear. Do not treat the headline potential value of a licensing agreement as available funding. If a payment depends on the same clinical result that the company needs cash to reach, it cannot solve the earlier funding gap. The terms covered in biotech licensing deal valuation can help identify which payments are dependable enough for the base forecast and which belong in contingent cases.
Update the funding bridge after each report
Maintain a short, dated model rather than carrying forward a single runway number. Reconcile the previous forecast with the newly reported cash balance and explain the difference. Separate changes caused by payment timing from changes in development scope. Then revisit the milestone date and spending assumptions. This process makes an unexpected cash movement useful: it becomes a question to investigate, not simply a reason to replace one estimate with another. Keep enough detail that another reader can reproduce the calculation without guessing which costs or receipts were included.
- Reconcile liquidity: identify available investments, restricted balances and completed financing proceeds.
- Explain burn changes: distinguish recurring development spending from exceptional payments and temporary working capital movements.
- Rebuild the calendar: update the expected evidence milestone and the spending required before and after it.
- Retest the funding gap: show cash at the milestone, cash above the reserve and the additional amount needed under a delay.
Carry the revised spending and financing assumptions into valuation sensitivity testing, particularly when launch timing or development scope has changed. Record what would invalidate the current funding case: a missed recruitment target, an additional production commitment, or a conditional receipt that does not arrive. The resulting investment note should state the balance date, the funded milestone and the remaining headroom. “Ten months of runway” leaves too much unsaid. “Funded to the expected readout, with $30 million above the operating reserve and no assumed future financing” gives the reader something that can be checked.